Research Article

Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases

Volume: 14 Number: 2 August 26, 2024
EN

Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases

Abstract

Objective: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), presents ongoing challenges in terms of diagnosis and management. With increasing treatment options, reliable markers for assessing treatment response have become crucial. This study explored the potential of apelin, a peptide hormone implicated in inflammation, as a biomarker for monitoring disease activity in patients with IBD undergoing colonoscopy. Materials and Methods: The study included 91 patients who were followed up for IBD. Apelin levels were measured in serum, and the site of involvement was simultaneously examined by colonoscopy. Alternations of apelin levels depending on the location of involvement was also considered. Results: Despite the widespread presence of apelin in the gastrointestinal system (GIS), our findings did not reveal significant differences in apelin levels among patients with varying colonoscopic involvement (p=0.73). Conclusion: Although apelin has potential as a biomarker of gastrointestinal inflammation in IBD, its precise role and clinical applicability necessitate comprehensive studies involving larger patient populations. Future research on apelin and IBD could refine its utility in disease monitoring and enhance its diagnostic significance.

Keywords

References

  1. 1. Kofla-Dlubacz A, Pytrus T, Akutko K, Sputa-Grzegrzölka P, Piotrowska A, Dziçgiel P. Etiology of IBD-is it stili a mystery? Int J Mol Sci 2022; 23(20): 12445. google scholar
  2. 2. Jarmakiewicz-Czaja S, Zielinska M, Sokal A, Filip R. Genetic and epigenetic etiology of ınflammatory bowel disease: an update. Genes (Basel) 2022; 13(12): 2388. google scholar
  3. 3. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life 2019; 12(2): 113-22. google scholar
  4. 4. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251(2): 471-6. google scholar
  5. 5. Földes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003; 308(3): 480-5. google scholar
  6. 6. Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008; 75(10): 1882-92. google scholar
  7. 7. Susaki E, Wang G, Cao G, Wang HQ, Englander EW, Greeley GH Jr. Apelin cells in the rat stomach. Regul Pept 2005; 129(1-3): 37-41. google scholar
  8. 8. Wang G, Anini Y, Wei W, Qi X, OCarroll AM, Mochizuki T, et al. Apelin, a new enteric peptide: localization in the gastrointestinal tract, ontogeny, and stimulation of gastric cell proliferation and of cholecystokinin secretion. Endocrinology 2004; 145(3): 1342-8. google scholar

Details

Primary Language

English

Subjects

Clinical Sciences (Other)

Journal Section

Research Article

Publication Date

August 26, 2024

Submission Date

June 3, 2024

Acceptance Date

August 5, 2024

Published in Issue

Year 2024 Volume: 14 Number: 2

APA
Değerli, E., Cesur, S., Yavuz, A., Değerli, M. S., & Karaali, Z. E. (2024). Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases. Experimed, 14(2), 126-130. https://doi.org/10.26650/experimed.1494644
AMA
1.Değerli E, Cesur S, Yavuz A, Değerli MS, Karaali ZE. Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases. Experimed. 2024;14(2):126-130. doi:10.26650/experimed.1494644
Chicago
Değerli, Ezgi, Selcan Cesur, Ahmet Yavuz, Mahmut Said Değerli, and Zeynep Ermiş Karaali. 2024. “Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases”. Experimed 14 (2): 126-30. https://doi.org/10.26650/experimed.1494644.
EndNote
Değerli E, Cesur S, Yavuz A, Değerli MS, Karaali ZE (August 1, 2024) Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases. Experimed 14 2 126–130.
IEEE
[1]E. Değerli, S. Cesur, A. Yavuz, M. S. Değerli, and Z. E. Karaali, “Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases”, Experimed, vol. 14, no. 2, pp. 126–130, Aug. 2024, doi: 10.26650/experimed.1494644.
ISNAD
Değerli, Ezgi - Cesur, Selcan - Yavuz, Ahmet - Değerli, Mahmut Said - Karaali, Zeynep Ermiş. “Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases”. Experimed 14/2 (August 1, 2024): 126-130. https://doi.org/10.26650/experimed.1494644.
JAMA
1.Değerli E, Cesur S, Yavuz A, Değerli MS, Karaali ZE. Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases. Experimed. 2024;14:126–130.
MLA
Değerli, Ezgi, et al. “Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases”. Experimed, vol. 14, no. 2, Aug. 2024, pp. 126-30, doi:10.26650/experimed.1494644.
Vancouver
1.Ezgi Değerli, Selcan Cesur, Ahmet Yavuz, Mahmut Said Değerli, Zeynep Ermiş Karaali. Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases. Experimed. 2024 Aug. 1;14(2):126-30. doi:10.26650/experimed.1494644